cas 2847-00-9|| where to buy (3AR,5R,6aS)-5-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[2,3-d][1,3]dioxol-6(3aH)-one

製品名:(3AR,5R,6aS)-5-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[2,3-d][1,3]dioxol-6(3aH)-one

IUPAC Name:(3aR,5R,6aS)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-tetrahydro-2H-furo[2,3-d][1,3]dioxol-6-one

包装単位	有効在庫	価格（USD）
CM196256-1g	in stock	ȖȖǫ
CM196256-5g	in stock	ǫŞŪ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2847-00-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2847-00-9; 分子式:C12H18O6; 融点:-; SMILESコード:O=C1[C@@H]([C@@H]2OC(C)(C)OC2)O[C@]3([H])OC(C)(C)O[C@@]31[H]; 密度:

: カタログ番号:CM196256; 分子量:258.27; 沸点:349.8°C at 760 mmHg; MDL番号:MFCD00040456; 保管方法:Store at 2-8°C.

: Carbohydrates; Carbohydrates are polyhydroxy aldehydes (aldoses) or polyhydroxy ketones (ketoses) composed of C, H and O, or form polyhydroxy aldehydes or ketones upon hydrolysis. Carbohydrates come in the form of monosaccharides, disaccharides, oligosaccharides and polysaccharides. The simplest sugars, monosaccharides and disaccharides, consist of one or two monosaccharide units. Oligosaccharides are generally classified as carbohydrates containing 3-10 monosaccharide units. Polysaccharides contain more than 10 monosaccharide units and can be quite large. Glucose is an aldose, the most important monosaccharide in the body, used by cells as fuel. Other aldohexoses are galactose and mannose, which form part of complex molecules. Fructose is a ketohexose sugar, while ribose is the most important aldose pentose sugar and a component of RNA.; best carbohydrate supplement; Looking for best carbohydrate supplement? We are waiting to create business relationship with you.

: Islatravir and Lenacapavir; Gilead and Merck announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class , long-acting HIV capsid inhibitor. At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study. Results of the primary endpoint (HIV-1 RNA ≥50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24;the participant later suppressed on islatravir and lenacapavir at Week 30.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.